Sara C Birtalan from Tucson, AZ, age 50

Binding Polypeptides With Restricted Diversity Sequences
view source
US Patent:

20070237764, Oct 11, 2007
Filed:

Dec 1, 2006
Appl. No.:

11/565880
Inventors:

Sara Birtalan - Menlo Park CA, US
Frederic Fellouse - Toronto, CA
Sachdev Sidhu - San Francisco CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C07K 16/18
A61K 39/395
C07H 21/04
C07K 16/46
C12N 5/16
G01N 33/563
C12N 15/63
C07K 1/00
C07K 14/00
US Classification:

424133100, 435326000, 436512000, 530350000, 530387100, 530387300, 536023530
Abstract:

The invention provides variant CDRs comprising highly restricted amino acid sequence diversity. These polypeptides provide a flexible and simple source of sequence diversity that can be used as a source for identifying novel antigen binding polypeptides. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.

Binding Polypeptides And Uses Thereof
view source
US Patent:

20070202552, Aug 30, 2007
Filed:

Dec 1, 2006
Appl. No.:

11/566120
Inventors:

Sachdev Sidhu - San Francisco CA, US
Sara Birtalan - Menlo Park CA, US
Frederic Fellouse - Toronto, CA
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

G01N 33/574
C40B 40/08
C40B 30/06
C07K 16/30
C07H 21/04
C12P 21/06
C12N 5/06
US Classification:

435007230, 435320100, 435326000, 530388800, 536023530, 435069100
Abstract:

The invention provides antibodies or antigen binding fragments thereof to DR5 and HER-2. The antibodies and/or antigen binding fragments thereof comprise variant CDRs comprising highly restricted amino acid sequence diversity. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. In addition, compositions and methods of use for treatment of cancer and immune related conditions are provided.